Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Hematology · GLRX5-Related Sideroblastic Anemia

Living With GLRX5: Monitoring and Daily Life

At a Glance

Living with GLRX5-related sideroblastic anemia requires an individualized plan to monitor blood counts and iron, use liver and heart MRI when needed, follow chelation safely, watch for neurologic changes, and seek practical and emotional support.

Living with a diagnosis as rare as GLRX5-related sideroblastic anemia means moving from the “search for an answer” into a lifelong rhythm of monitoring and management. Because there are no universal guidelines for this specific gene, your care will be a partnership between your family and a specialized medical team, focusing on protecting the organs from iron and monitoring for neurological involvement when indicated [1][2].

The Surveillance Rhythm: Protecting the Organs

A critical part of daily life with GLRX5 is staying ahead of iron overload. In this condition, the body absorbs extra iron even if an individual is not receiving transfusions—a process called ineffective erythropoiesis [3][4]. Important Warning: Never begin iron supplements or iron-containing over-the-counter products unless the treating team has documented true iron deficiency and explicitly recommended them.

  • Routine Blood Work: You can expect Complete Blood Counts (CBC) to monitor hemoglobin levels and ferritin tests to track iron storage. The frequency of these tests will be individualized by your clinician based on age, symptoms, and transfusion status [1][5].
  • Iron MRI Estimates: Ferritin levels don’t always tell the whole story. Specialized MRI scans—like a FerriScan (R2 MRI) for the liver and a cardiac T2 MRI* for the heart—are used to provide validated estimates of tissue iron [1][6]. The treating center sets this schedule based on transfusion burden and clinical need.
  • Chelation Adherence: If prescribed iron chelation (like deferasirox), safe adherence is vital. If a dose is missed, follow the practical, non-blaming instructions provided by your team—do not assume a single missed dose causes immediate organ damage, but also be aware that excessive chelation can cause harm. Contact the team about any toxicity, adverse effects (like new renal, hepatic, or visual/hearing symptoms), or barriers to adherence [3][7].

Monitoring the Nervous System (Syndromic Form)

If the neurological phenotype is suspected or confirmed, your team will track specific milestones when indicated [2]. The natural history of reported GLRX5 neurological disease remains uncertain.

  • Motor and Gait Assessments: Doctors will evaluate for signs of spasticity (muscle tightness) or neuropathy (nerve damage). Report any “regression,” such as suddenly having trouble with a task previously mastered [2][8].
  • Metabolic Checks: Glycine testing is tied to a documented or suspected metabolic phenotype [2].
  • Swallow Safety: If symptoms like coughing with meals or a wet voice appear, an assessment by a speech-language pathologist can ensure swallowing is safe and prevent aspiration [9][10].

The Psychosocial Journey

Navigating an ultra-rare disease carries a high emotional and physical load.

  • The Weight of Uncertainty: Patients and caregivers often report “care overload” and high levels of anxiety and stress [11][12]. “Scanxiety” is commonly used to describe the worry felt before routine monitoring tests.
  • Building a Support Map: Research shows that having strong social support and adaptive coping strategies (like focusing on manageable daily goals) improves quality of life [13][14]. Ask for referrals to a genetic counselor, social worker, or reputable rare-disease organizations for help with school/workplace accommodations, travel, and emotional support.
  • Connecting with Rare Communities: Even if you cannot find someone with the exact GLRX5 mutation, broader Sideroblastic Anemia or Mitochondrial Disease support groups can provide shared wisdom [15][16].

Managing GLRX5 requires a clinician-planned framework. By maintaining an individualized surveillance schedule and prioritizing mental health, you create the most stable environment to thrive.

Common questions in this guide

What monitoring is needed for GLRX5-related sideroblastic anemia?
Monitoring may include complete blood counts and ferritin tests, along with liver iron and cardiac iron MRI scans when clinically indicated. The medical team individualizes the schedule according to age, symptoms, iron status, and transfusion history.
Can iron overload occur without blood transfusions in GLRX5 anemia?
Yes. Ineffective red blood cell production can cause the body to absorb extra iron even when a person does not receive transfusions. Do not take iron supplements or iron-containing products unless true iron deficiency has been documented and the treating team recommends them.
What are liver and heart iron MRI scans used for?
A liver R2 MRI, sometimes called a FerriScan, estimates iron stored in the liver, while a cardiac T2* MRI estimates iron in the heart. These tests can provide information that ferritin blood levels do not always show, and their timing depends on clinical need.
What should I do if I miss a dose of iron chelation medicine?
Follow the missed-dose instructions provided by your treating team rather than guessing or taking extra medicine. A single missed dose does not usually cause immediate organ damage, but excessive chelation can be harmful, so report side effects or barriers to taking the medicine.
Which neurological changes should be reported?
Report new stiffness, changes in walking, foot dragging, frequent tripping, nerve symptoms, or loss of a previously mastered skill. Coughing during meals or a wet-sounding voice may also signal a need for a swallowing safety assessment.
Where can families find support when living with GLRX5-related sideroblastic anemia?
A genetic counselor or social worker can help with emotional support, school or workplace accommodations, travel planning, and connections to rare-disease resources. Sideroblastic anemia and mitochondrial disease communities may offer useful support even when an exact GLRX5 mutation is uncommon.

Get notified when new evidence is published on anemia, sideroblastic, 5.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (16)
  1. 1

    Non syndromic childhood onset congenital sideroblastic anemia: A report of 13 patients identified with an ALAS2 or SLC25A38 mutation.

    Le Rouzic MA, Fouquet C, Leblanc T, et al.

    Blood cells, molecules & diseases 2017; (66()):11-18 doi:10.1016/j.bcmd.2017.07.003.

    PMID: 28772256
  2. 2

    GLRX5-associated [Fe-S] cluster biogenesis disorder: further characterisation of the neurological phenotype and long-term outcome.

    Sankaran BP, Gupta S, Tchan M, et al.

    Orphanet journal of rare diseases 2021; (16(1)):465 doi:10.1186/s13023-021-02073-z.

    PMID: 34732213
  3. 3

    Clinical characterization and hematopoietic stem cell transplant outcomes for congenital sideroblastic anemia caused by a novel pathogenic variant in SLC25A38.

    Uminski K, Houston DS, Hartley JN, et al.

    Pediatric blood & cancer 2020; (67(10)):e28623 doi:10.1002/pbc.28623.

    PMID: 32790119
  4. 4

    Pathophysiology and classification of iron overload diseases; update 2018.

    Brissot P, Troadec MB, Loréal O, Brissot E

    Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine 2019; (26(1)):80-88 doi:10.1016/j.tracli.2018.08.006.

    PMID: 30173950
  5. 5

    IARS2-related disease manifesting as sideroblastic anemia and hypoparathyroidism: A case report.

    Gong Y, Lan XP, Guo S

    Frontiers in pediatrics 2022; (10()):1080664 doi:10.3389/fped.2022.1080664.

    PMID: 36704128
  6. 6

    Genotype/phenotype correlations of childhood-onset congenital sideroblastic anaemia in a European cohort.

    Fouquet C, Le Rouzic MA, Leblanc T, et al.

    British journal of haematology 2019; (187(4)):530-542 doi:10.1111/bjh.16100.

    PMID: 31338833
  7. 7

    A novel and apparent de novo ALAS2 missense variant associated with congenital sideroblastic anemia.

    Cai J, Liu T, Huang Y, et al.

    Frontiers in pediatrics 2024; (12()):1411676 doi:10.3389/fped.2024.1411676.

    PMID: 39281190
  8. 8

    Teaching NeuroImage: Glutaredoxin-5-Associated Variant Nonketotic Hyperglycinemia.

    Roy Chowdhury S, Mittal R, Yadav R, Guglany V

    Neurology 2024; (102(3)):e208105 doi:10.1212/WNL.0000000000208105.

    PMID: 38175985
  9. 9

    Infant With a Severe Form of GLRX5-Related Atypical Hyperglycinemia Exhibiting Novel Cardiac and Neurologic Disease Manifestations at Autopsy.

    Ferreira EO, Del Bigio MR, Morin J, Frosk P

    Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society 2025; (28(5)):390-394 doi:10.1177/10935266251335065.

    PMID: 40415601
  10. 10

    Primary mitochondrial myopathies in childhood.

    Olimpio C, Tiet MY, Horvath R

    Neuromuscular disorders : NMD 2021; (31(10)):978-987 doi:10.1016/j.nmd.2021.08.005.

    PMID: 34736635
  11. 11

    Assessing Psychological Harms on Parents and Primary Caregivers of Children Living with a Rare Disease: A Systematic Review of the Scope and Validity of Surveys Utilized.

    Bull LJ, Eslick GD, Teutsch SM, Elliott EJ

    Clinical child and family psychology review 2025; (28(3)):612-630 doi:10.1007/s10567-025-00533-7.

    PMID: 40588644
  12. 12

    Comparison of parental caregivers and associated factors with caregiver burden in rare paediatric diseases.

    Brandt M, Inhestern L, Zybarth D, et al.

    Orphanet journal of rare diseases 2026; (21(1)).

    PMID: 42881418
  13. 13

    Prevalence of depression and anxiety, and their relationship to social support among patients and family caregivers of rare bone diseases.

    Lai X, Jiang Y, Sun Y, et al.

    Orphanet journal of rare diseases 2023; (18(1)):18 doi:10.1186/s13023-022-02611-3.

    PMID: 36703212
  14. 14

    Stress, coping, and positive aspects of caregiving among caregivers of children with rare disease.

    Manalel JA, Sumrall S, Davidson H, et al.

    Psychology & health 2024; (39(2)):216-232 doi:10.1080/08870446.2022.2057494.

    PMID: 35620936
  15. 15

    A "rotating menu" of medical uncertainty for families affected by telomere biology disorders: A qualitative interview study.

    Pearce E, Majid A, Brown T, et al.

    SSM. Qualitative research in health 2024; (6()) doi:10.1016/j.ssmqr.2024.100486.

    PMID: 39554689
  16. 16

    Pearson syndrome.

    Farruggia P, Di Marco F, Dufour C

    Expert review of hematology 2018; (11(3)):239-246 doi:10.1080/17474086.2018.1426454.

    PMID: 29337599

This page is for informational purposes only and does not constitute medical advice. Your hematology and specialist team should tailor monitoring, chelation, and neurologic care to your GLRX5-related sideroblastic anemia.

Guide contents anemia, sideroblastic, 5
Research & Literature
05 Standard Treatments and Curative Options